Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) Given Average Rating of “Buy” by Analysts

Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) has received an average rating of “Buy” from the nine brokerages that are presently covering the stock, MarketBeat Ratings reports. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among brokerages that have covered the stock in the last year is $32.25.

A number of research analysts have recently weighed in on CPRX shares. Robert W. Baird initiated coverage on Catalyst Pharmaceuticals in a research report on Tuesday, February 4th. They issued an “outperform” rating and a $28.00 price target for the company. HC Wainwright increased their price objective on Catalyst Pharmaceuticals from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday, January 10th. Truist Financial increased their price objective on Catalyst Pharmaceuticals from $30.00 to $36.00 and gave the company a “buy” rating in a research note on Monday, November 11th. Bank of America reaffirmed a “buy” rating and set a $30.00 price objective on shares of Catalyst Pharmaceuticals in a research note on Thursday, January 9th. Finally, StockNews.com lowered Catalyst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 11th.

Catalyst Pharmaceuticals Stock Down 1.1 %

Shares of CPRX stock opened at $20.58 on Thursday. Catalyst Pharmaceuticals has a fifty-two week low of $14.16 and a fifty-two week high of $24.64. The stock has a market cap of $2.45 billion, a P/E ratio of 17.44, a P/E/G ratio of 3.31 and a beta of 0.80. The business has a fifty day simple moving average of $22.21 and a 200-day simple moving average of $21.40.

Insiders Place Their Bets

In other news, insider Steve Miller sold 50,000 shares of Catalyst Pharmaceuticals stock in a transaction dated Tuesday, December 10th. The stock was sold at an average price of $21.93, for a total value of $1,096,500.00. Following the transaction, the insider now directly owns 686,996 shares of the company’s stock, valued at $15,065,822.28. The trade was a 6.78 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this link. 11.00% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Catalyst Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. Steward Partners Investment Advisory LLC acquired a new position in shares of Catalyst Pharmaceuticals in the 4th quarter valued at about $27,000. Farther Finance Advisors LLC raised its holdings in shares of Catalyst Pharmaceuticals by 125.1% during the 4th quarter. Farther Finance Advisors LLC now owns 2,690 shares of the biopharmaceutical company’s stock valued at $56,000 after buying an additional 1,495 shares during the period. Larson Financial Group LLC raised its holdings in shares of Catalyst Pharmaceuticals by 27,218.2% during the 3rd quarter. Larson Financial Group LLC now owns 3,005 shares of the biopharmaceutical company’s stock valued at $60,000 after buying an additional 2,994 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in shares of Catalyst Pharmaceuticals during the 4th quarter valued at about $65,000. Finally, KBC Group NV raised its holdings in shares of Catalyst Pharmaceuticals by 48.8% during the 4th quarter. KBC Group NV now owns 4,699 shares of the biopharmaceutical company’s stock valued at $98,000 after buying an additional 1,542 shares during the period. 79.22% of the stock is owned by institutional investors and hedge funds.

About Catalyst Pharmaceuticals

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.